These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 37198894)

  • 1. Comparison of differing dose levels of methotrexate for patients with primary central nervous system lymphoma.
    Schrum DP; Moorman MT; Li Z; Dillon M; Peters KB; McKinney M; Patel MP
    J Oncol Pharm Pract; 2024 Apr; 30(3):513-518. PubMed ID: 37198894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of methotrexate exposure on outcome in patients treated with MBVP chemotherapy for primary central nervous system lymphoma.
    Blasco H; Senecal D; Le Gouge A; Pinard E; Benz-de Bretagne I; Colombat P; Hulot JS; Chatelut E; Le Guellec C
    Br J Clin Pharmacol; 2010 Sep; 70(3):367-75. PubMed ID: 20716237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is intrathecal methotrexate necessary in the treatment of primary CNS lymphoma?
    Khan RB; Shi W; Thaler HT; DeAngelis LM; Abrey LE
    J Neurooncol; 2002 Jun; 58(2):175-8. PubMed ID: 12164690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes of older patients with primary central nervous system lymphoma treated in routine clinical practice in the UK: methotrexate dose intensity correlates with response and survival.
    Martinez-Calle N; Poynton E; Alchawaf A; Kassam S; Horan M; Rafferty M; Kelsey P; Scott G; Culligan DJ; Buckley H; Lim YJ; Ngu L; McCulloch R; Rowntree C; Wright J; McKay P; Fourali S; Eyre TA; Smith J; Osborne W; Yallop D; Linton K; Fox CP; Cwynarski K
    Br J Haematol; 2020 Aug; 190(3):394-404. PubMed ID: 32232989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of chemotherapy additional to high-dose methotrexate for primary central nervous system lymphoma (PCNSL).
    Bergner N; Monsef I; Illerhaus G; Engert A; Skoetz N
    Cochrane Database Syst Rev; 2012 Nov; 11():CD009355. PubMed ID: 23152274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical utility and pharmacology of high-dose methotrexate in the treatment of primary CNS lymphoma.
    Green MR; Chowdhary S; Lombardi KM; Chalmers LM; Chamberlain M
    Expert Rev Neurother; 2006 May; 6(5):635-52. PubMed ID: 16734512
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial.
    Thiel E; Korfel A; Martus P; Kanz L; Griesinger F; Rauch M; Röth A; Hertenstein B; von Toll T; Hundsberger T; Mergenthaler HG; Leithäuser M; Birnbaum T; Fischer L; Jahnke K; Herrlinger U; Plasswilm L; Nägele T; Pietsch T; Bamberg M; Weller M
    Lancet Oncol; 2010 Nov; 11(11):1036-47. PubMed ID: 20970380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
    Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
    Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urine volume to hydration volume ratio is associated with pharmacokinetics of high-dose methotrexate in patients with primary central nervous system lymphoma.
    Isono T; Hira D; Morikochi A; Fukami T; Ueshima S; Nozaki K; Terada T; Morita SY
    Pharmacol Res Perspect; 2021 Dec; 9(6):e00883. PubMed ID: 34664791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial.
    Omuro A; Chinot O; Taillandier L; Ghesquieres H; Soussain C; Delwail V; Lamy T; Gressin R; Choquet S; Soubeyran P; Huchet A; Benouaich-Amiel A; Lebouvier-Sadot S; Gyan E; Touitou V; Barrié M; del Rio MS; Gonzalez-Aguilar A; Houillier C; Delgadillo D; Lacomblez L; Tanguy ML; Hoang-Xuan K
    Lancet Haematol; 2015 Jun; 2(6):e251-9. PubMed ID: 26688235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of HD-MTX based systemic chemotherapy regimens: retrospective study of induction therapy for primary central nervous system lymphoma in Chinese.
    Han X; Ji Y; Ouyang M; Zhu T; Zhou D
    Sci Rep; 2017 Dec; 7(1):17053. PubMed ID: 29213063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose methotrexate for elderly patients with primary CNS lymphoma.
    Zhu JJ; Gerstner ER; Engler DA; Mrugala MM; Nugent W; Nierenberg K; Hochberg FH; Betensky RA; Batchelor TT
    Neuro Oncol; 2009 Apr; 11(2):211-5. PubMed ID: 18757775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparing the Efficacy of DeVIC Therapy and High-dose Methotrexate Monotherapy with Whole-brain Radiation Therapy for Newly-diagnosed Primary Central Nervous System Lymphoma: A Single Institution Study.
    Chalise L; Motomura K; Ohka F; Hirano M; Hara M; Nishimura Y; Natsume A; Wakabayashi T
    Anticancer Res; 2017 Sep; 37(9):5215-5223. PubMed ID: 28870957
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prospective phase II trial of response adapted whole brain radiotherapy after high dose methotrexate based chemotherapy in patients with newly diagnosed primary central nervous system lymphoma-analysis of acute toxicity profile and early clinical outcome.
    Adhikari N; Biswas A; Gogia A; Sahoo RK; Garg A; Nehra A; Sharma MC; Bhasker S; Singh M; Sreenivas V; Chawla R; Joshi G; Kumar L; Chander S
    J Neurooncol; 2018 Aug; 139(1):153-166. PubMed ID: 29633112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma--a randomized phase III trial (MATRix).
    Schorb E; Finke J; Ferreri AJ; Ihorst G; Mikesch K; Kasenda B; Fritsch K; Fricker H; Burger E; Grishina O; Valk E; Zucca E; Illerhaus G
    BMC Cancer; 2016 Apr; 16():282. PubMed ID: 27098429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study.
    Bromberg JEC; Issa S; Bakunina K; Minnema MC; Seute T; Durian M; Cull G; Schouten HC; Stevens WBC; Zijlstra JM; Baars JW; Nijland M; Mason KD; Beeker A; van den Bent MJ; Beijert M; Gonzales M; de Jong D; Doorduijn JK
    Lancet Oncol; 2019 Feb; 20(2):216-228. PubMed ID: 30630772
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical significance of polyglutamylation in primary central nervous system lymphoma.
    Shinojima N; Fujimoto K; Makino K; Todaka K; Yamada K; Mikami Y; Oda K; Nakamura K; Jono H; Kuratsu JI; Nakamura H; Yano S; Mukasa A
    Acta Neuropathol Commun; 2018 Feb; 6(1):15. PubMed ID: 29475458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined treatment with high-dose methotrexate, vincristine and procarbazine, without intrathecal chemotherapy, followed by consolidation radiotherapy for primary central nervous system lymphoma in immunocompetent patients.
    Ferreri AJ; Reni M; Dell'Oro S; Ciceri F; Bernardi M; Camba L; Ponzoni M; Terreni MR; Tomirotti M; Spina M; Villa E
    Oncology; 2001; 60(2):134-40. PubMed ID: 11244328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose methotrexate for primary CNS lymphoma in the elderly.
    Ng S; Rosenthal MA; Ashley D; Cher L
    Neuro Oncol; 2000 Jan; 2(1):40-4. PubMed ID: 11302253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of Key Factors Associated with Response to Salvage High-Dose Methotrexate Rechallenge in Primary Central Nervous System Lymphoma with First Relapse.
    Du P; Chen H; Shen L; Liu X; Wu X; Chen L; Cao A; Geng D
    Curr Oncol; 2022 Sep; 29(9):6642-6656. PubMed ID: 36135091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.